Regulatory Reactivity in FDA's Approval of the Alzheimer's Disease Drug Aducanumab (Aduhelm)

Yaniv Heled (Georgia State University), Ana Santos Rutschman (Saint Louis University), Liza Vertinsky (Emory University), Regulatory Reactivity in FDA's Approval of the Alzheimer's Disease Drug Aducanumab (Aduhelm), Regul. Rev. (2021): On June 7, 2021, the U.S. Food and Drug Administration...

https://lawprofessors.typepad.com/healthlawprof_blog/2021/10/regulatory-reactivi...

Source: HealthLawProf Blog - October 22, 2021 Category: Medical Law Authors: Katharine Van Tassel Source Type: blogs

More News: Alzheimer's | Blogging | Food and Drug Administration (FDA) | Georgia Health | Medical Law